Idera Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IDRA)

$2.41 -0.08 (-3.21 %)
(As of 01/17/2018 08:07 AM ET)
Previous Close$2.49
Today's Range$2.37 - $2.50
52-Week Range$1.30 - $2.87
Volume2.43 million shs
Average Volume1.57 million shs
Market Capitalization$485.23 million
P/E Ratio-7.30
Dividend YieldN/A
Beta2.19

About Idera Pharmaceuticals (NASDAQ:IDRA)

Idera Pharmaceuticals logoIdera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

Receive IDRA News and Ratings via Email

Sign-up to receive the latest news and ratings for IDRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IDRA
CUSIPN/A
Phone617-679-5500

Debt

Debt-to-Equity RatioN/A
Current Ratio8.84%
Quick Ratio8.84%

Price-To-Earnings

Trailing P/E Ratio-7.3028090057877
Forward P/E Ratio-5.74
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.20 million
Price / Sales28.99
Cash FlowN/A
Price / CashN/A
Book Value$0.70 per share
Price / Book3.44

Profitability

Trailing EPS($0.33)
Net Income$-38,380,000.00
Net Margins-313.78%
Return on Equity-60.80%
Return on Assets-55.07%

Miscellaneous

Employees62
Outstanding Shares194,870,000

Idera Pharmaceuticals (NASDAQ:IDRA) Frequently Asked Questions

What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals Inc (NASDAQ:IDRA) issued its quarterly earnings data on Monday, November, 6th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.12) by $0.02. The biotechnology company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.20 million. Idera Pharmaceuticals had a negative return on equity of 60.80% and a negative net margin of 313.78%. View Idera Pharmaceuticals' Earnings History.

Where is Idera Pharmaceuticals' stock going? Where will Idera Pharmaceuticals' stock price be in 2018?

5 brokerages have issued 12 month target prices for Idera Pharmaceuticals' shares. Their forecasts range from $4.00 to $8.00. On average, they anticipate Idera Pharmaceuticals' share price to reach $5.40 in the next year. View Analyst Ratings for Idera Pharmaceuticals.

What are Wall Street analysts saying about Idera Pharmaceuticals stock?

Here are some recent quotes from research analysts about Idera Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera's proprietary drug candidates are designed to modulate Toll-like Receptors, the body's first line of immune defense. Idera's pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances. " (1/17/2018)
  • 2. Wedbush analysts commented, "IDRA is focused on pursuing an aggressive development strategy for IMO-2125 in light of durable responses in its ongoing Ph 1 study in PD-1 refractory melanoma. We believe the recently presented translational data demonstrating evidence of mechanism support a wider opportunity in improving the response to checkpoint agents in additional immunogenic tumors, as potentially broadening their utility to less immunogenic tumors." (1/31/2017)

Who are some of Idera Pharmaceuticals' key competitors?

Who are Idera Pharmaceuticals' key executives?

Idera Pharmaceuticals' management team includes the folowing people:

  • James A. Geraghty, Independent Chairman of the Board (Age 62)
  • Vincent J. Milano, President, Chief Executive Officer, Director (Age 53)
  • Louis J. Arcudi III, Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary (Age 54)
  • Robert Clayton Fletcher, Senior Vice President - Business Development and Strategic Planning (Age 53)
  • Joanna C. Horobin M.D., Senior Vice President, Chief Medical Officer (Age 61)
  • Robert A. Doody Jr., Vice President - Investor Relations and Corporate Communications
  • William S. Reardon CPA, Lead Independent Director (Age 71)
  • Maxine Gowen Ph.D., Director (Age 59)
  • Julian C. Baker, Independent Director (Age 50)
  • Mark Alan Goldberg M.D., Independent Director (Age 62)

Who owns Idera Pharmaceuticals stock?

Idera Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BAKER BROS. ADVISORS LP (9.90%). Company insiders that own Idera Pharmaceuticals stock include Bros Advisors Lp Baker, Invest Corp Pillar, James A Geraghty, Julian Baker, Mark J Casey, Maxine Gowen and Vincent Milano. View Institutional Ownership Trends for Idera Pharmaceuticals.

How do I buy Idera Pharmaceuticals stock?

Shares of Idera Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Idera Pharmaceuticals' stock price today?

One share of Idera Pharmaceuticals stock can currently be purchased for approximately $2.41.

How big of a company is Idera Pharmaceuticals?

Idera Pharmaceuticals has a market capitalization of $485.23 million and generates $16.20 million in revenue each year. The biotechnology company earns $-38,380,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Idera Pharmaceuticals employs 62 workers across the globe.

How can I contact Idera Pharmaceuticals?

Idera Pharmaceuticals' mailing address is 167 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-679-5500 or via email at [email protected]


MarketBeat Community Rating for Idera Pharmaceuticals (IDRA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  96 (Vote Underperform)
Total Votes:  257
MarketBeat's community ratings are surveys of what our community members think about Idera Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Idera Pharmaceuticals (NASDAQ:IDRA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.40$5.40$5.75$5.28
Price Target Upside: 172.73% upside172.73% upside179.81% upside134.44% upside

Idera Pharmaceuticals (NASDAQ:IDRA) Consensus Price Target History

Price Target History for Idera Pharmaceuticals (NASDAQ:IDRA)

Idera Pharmaceuticals (NASDAQ:IDRA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2017HC WainwrightSet Price TargetBuy$4.00N/AView Rating Details
9/12/2017Piper Jaffray CompaniesReiterated RatingBuy$4.00LowView Rating Details
4/24/2017Robert W. BairdInitiated CoverageOutperform -> Outperform$5.00MediumView Rating Details
4/11/2017WedbushReiterated RatingOutperform$6.00LowView Rating Details
3/22/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$8.00HighView Rating Details
11/29/2016CowenReiterated RatingOutperformN/AView Rating Details
10/7/2016S&P Equity ResearchBoost Price Target$1.86 -> $2.10N/AView Rating Details
(Data available from 1/17/2016 forward)

Earnings

Idera Pharmaceuticals (NASDAQ:IDRA) Earnings History and Estimates Chart

Earnings by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)

Idera Pharmaceuticals (NASDAQ IDRA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($0.12)($0.10)$0.20 million$0.16 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.11)($0.14)$0.20 million$0.19 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.10)($0.10)$0.20 million$0.38 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.11)$0.01$0.32 million$15.28 millionViewN/AView Earnings Details
10/28/2016Q3($0.11)($0.10)$0.30 million$0.32 millionViewN/AView Earnings Details
8/2/2016Q216($0.11)($0.11)$0.30 million$0.30 millionViewN/AView Earnings Details
5/9/2016Q1($0.11)($0.11)$0.20 million$0.29 millionViewListenView Earnings Details
3/10/2016Q4($0.11)($0.10)$0.03 million$0.19 millionViewN/AView Earnings Details
11/6/2015Q315($0.11)($0.10)$0.02 millionViewN/AView Earnings Details
8/6/2015Q215($0.11)($0.11)$0.01 millionViewN/AView Earnings Details
5/11/2015Q1($0.11)($0.12)$0.03 million$0.03 millionViewN/AView Earnings Details
3/12/2015Q414($0.11)($0.14)$0.03 millionViewN/AView Earnings Details
11/7/2014Q314($0.11)($0.11)$0.03 millionViewListenView Earnings Details
8/12/2014Q214($0.09)($0.10)$0.04 millionViewListenView Earnings Details
5/13/2014Q114($0.08)($0.12)ViewListenView Earnings Details
3/13/2014Q4($0.08)($0.10)ViewListenView Earnings Details
11/14/2013Q3($0.11)($0.11)$0.03 million$0.01 millionViewListenView Earnings Details
8/15/2013Q213($0.12)($0.15)ViewN/AView Earnings Details
5/15/2013Q113($0.19)($0.15)ViewN/AView Earnings Details
3/11/2013Q4 2012($0.24)ViewN/AView Earnings Details
11/12/2012Q312($0.17)ViewN/AView Earnings Details
8/9/2012Q2 2012($0.15)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.26)($0.22)ViewN/AView Earnings Details
3/14/2012Q4 2011($0.21)($0.40)ViewN/AView Earnings Details
11/9/2011Q3 2011($0.20)($0.20)ViewN/AView Earnings Details
8/5/2011Q2 2011($0.25)($0.23)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.20)($0.25)ViewN/AView Earnings Details
3/10/2011Q4 2010($0.24)($0.22)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.06)($0.18)ViewN/AView Earnings Details
8/5/2010Q2 2010$0.02($0.23)ViewN/AView Earnings Details
5/4/2010Q1 2010($0.01)($0.08)ViewN/AView Earnings Details
3/10/2010Q4 2009$0.17ViewN/AView Earnings Details
8/4/2009Q2 2009($0.01)$0.16ViewN/AView Earnings Details
5/6/2009Q1 2009$0.01($0.01)ViewN/AView Earnings Details
3/11/2009Q4 2008$0.01$0.02ViewN/AView Earnings Details
11/6/2008Q3 2008($0.03)$0.08ViewN/AView Earnings Details
8/1/2008Q2 2008($0.09)$0.05ViewN/AView Earnings Details
5/12/2008Q1 2008$0.39($0.10)ViewN/AView Earnings Details
3/4/2008Q4 2007($0.18)($0.21)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Idera Pharmaceuticals (NASDAQ:IDRA) Earnings Estimates

2018 EPS Consensus Estimate: ($0.37)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.09)($0.09)($0.09)
Q2 20181($0.09)($0.09)($0.09)
Q3 20181($0.09)($0.09)($0.09)
Q4 20181($0.10)($0.10)($0.10)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Idera Pharmaceuticals (NASDAQ:IDRA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Idera Pharmaceuticals (NASDAQ IDRA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.42%
Institutional Ownership Percentage: 24.14%
Insider Trades by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)
Institutional Ownership by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)

Idera Pharmaceuticals (NASDAQ IDRA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2017Invest Corp PillarMajor ShareholderSell2,300,000$1.96$4,508,000.00View SEC Filing  
12/13/2017Invest Corp PillarMajor ShareholderSell1,100,000$1.93$2,123,000.00View SEC Filing  
10/26/2017Bros. Advisors Lp BakerDirectorBuy8,000,000$1.50$12,000,000.00View SEC Filing  
5/1/2017Invest Corp PillarDirectorSell450,815$2.26$1,018,841.90View SEC Filing  
4/25/2017Invest Corp PillarDirectorSell1,328,422$2.29$3,042,086.38View SEC Filing  
4/24/2017Invest Corp PillarDirectorSell437,829$2.29$1,002,628.41View SEC Filing  
10/7/2016Julian BakerDirectorBuy3,250,000$2.00$6,500,000.00View SEC Filing  
10/3/2016Maxine GowenDirectorBuy4,102$2.56$10,501.1210,543View SEC Filing  
5/13/2016James A GeraghtyDirectorBuy10,000$1.34$13,400.00425,649View SEC Filing  
5/12/2016Mark J CaseyVPBuy34,450$1.44$49,608.0034,450View SEC Filing  
3/15/2016Vincent MilanoCEOBuy40,000$1.97$78,800.00246,527View SEC Filing  
2/13/2015Julian BakerDirectorBuy5,333,333$3.75$19,999,998.75View SEC Filing  
12/16/2014Youssef El ZeinDirectorSell100,000$3.68$368,000.00View SEC Filing  
12/12/2014Vincent MilanoCEOBuy200,000$4.00$800,000.00View SEC Filing  
5/27/2014James A GeraghtyDirectorBuy10,000$2.65$26,500.00View SEC Filing  
12/6/2013James A GeraghtyDirectorBuy40,000$2.72$108,800.00View SEC Filing  
9/16/2013James A GeraghtyDirectorBuy60,000$1.90$114,000.00View SEC Filing  
8/19/2013James A GeraghtyDirectorBuy300,000$1.75$525,000.00View SEC Filing  
5/7/2013C Keith HartleyDirectorBuy90,000$0.49$44,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Idera Pharmaceuticals (NASDAQ IDRA) News Headlines

Source:
DateHeadline
Idera Pharmaceuticals Inc (IDRA) Given Consensus Rating of "Buy" by AnalystsIdera Pharmaceuticals Inc (IDRA) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - January 16 at 4:02 AM
Idera Pharmaceuticals Provides 2018 Update and Outlook - GlobeNewswire (press release)Idera Pharmaceuticals Provides 2018 Update and Outlook - GlobeNewswire (press release)
globenewswire.com - January 7 at 8:43 PM
Idera Pharmaceuticals provides 2018 update and outlook - Seeking AlphaIdera Pharmaceuticals provides 2018 update and outlook - Seeking Alpha
seekingalpha.com - January 6 at 3:30 PM
Idera Pharma (IDRA) Provides 2018 Update, OutlookIdera Pharma (IDRA) Provides 2018 Update, Outlook
www.streetinsider.com - January 5 at 10:02 AM
Where Idera Pharmaceuticals Inc (NASDAQ:IDRA) Stands In Terms Of Earnings Growth Against Its IndustryWhere Idera Pharmaceuticals Inc (NASDAQ:IDRA) Stands In Terms Of Earnings Growth Against Its Industry
finance.yahoo.com - January 3 at 3:28 PM
Idera Pharmaceuticals (IDRA) Lifted to Buy at BidaskClubIdera Pharmaceuticals (IDRA) Lifted to Buy at BidaskClub
www.americanbankingnews.com - December 30 at 2:54 PM
Idera Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IDRA) : December 26, 2017Idera Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IDRA) : December 26, 2017
finance.yahoo.com - December 26 at 3:06 PM
Idera Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IDRA-US : December 22, 2017Idera Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IDRA-US : December 22, 2017
finance.yahoo.com - December 22 at 9:53 AM
Idera Pharmaceuticals, Inc. (IDRA) Given Consensus Recommendation of "Buy" by BrokeragesIdera Pharmaceuticals, Inc. (IDRA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 22 at 3:58 AM
ETFs with exposure to Idera Pharmaceuticals, Inc. : December 20, 2017ETFs with exposure to Idera Pharmaceuticals, Inc. : December 20, 2017
finance.yahoo.com - December 20 at 3:28 PM
Insider Selling: Idera Pharmaceuticals, Inc. (IDRA) Major Shareholder Sells 2,300,000 Shares of StockInsider Selling: Idera Pharmaceuticals, Inc. (IDRA) Major Shareholder Sells 2,300,000 Shares of Stock
www.americanbankingnews.com - December 15 at 8:52 PM
Idera Pharmaceuticals, Inc. (IDRA) Major Shareholder Sells $2,123,000.00 in StockIdera Pharmaceuticals, Inc. (IDRA) Major Shareholder Sells $2,123,000.00 in Stock
www.americanbankingnews.com - December 15 at 8:52 PM
Analyzing Rosetta Genomics (ROSG) and Idera Pharmaceuticals (IDRA)Analyzing Rosetta Genomics (ROSG) and Idera Pharmaceuticals (IDRA)
www.americanbankingnews.com - December 12 at 9:18 AM
Idera Pharmaceuticals (IDRA) Downgraded by BidaskClub to HoldIdera Pharmaceuticals (IDRA) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - December 9 at 5:46 PM
ETFs with exposure to Idera Pharmaceuticals, Inc. : December 8, 2017ETFs with exposure to Idera Pharmaceuticals, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 3:28 PM
This Mornings Technical Outlook on Biotech Stocks -- DelMar Pharma, Galena Biopharma, Heat Biologics, and Idera ... - PR Newswire (press release)This Morning's Technical Outlook on Biotech Stocks -- DelMar Pharma, Galena Biopharma, Heat Biologics, and Idera ... - PR Newswire (press release)
www.prnewswire.com - December 1 at 12:28 PM
Idera Pharma (IDRA) Granted FDA Fast Track Designation for IMO-2125 in Combination with Ipilimumab - StreetInsider.comIdera Pharma (IDRA) Granted FDA Fast Track Designation for IMO-2125 in Combination with Ipilimumab - StreetInsider.com
www.streetinsider.com - December 1 at 12:28 PM
Wired News – Idera Pharma Gets Fast Track Designation for IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic MelanomaWired News – Idera Pharma Gets Fast Track Designation for IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma
finance.yahoo.com - December 1 at 12:28 PM
Phase 3 Trial Initiation Planned for First Quarter 2018Phase 3 Trial Initiation Planned for First Quarter 2018
globenewswire.com - November 29 at 9:48 AM
U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals’ IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic MelanomaU.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals’ IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma
finance.yahoo.com - November 29 at 9:48 AM
Idera Pharmaceuticals, Inc. (IDRA) Sees Large Growth in Short InterestIdera Pharmaceuticals, Inc. (IDRA) Sees Large Growth in Short Interest
www.americanbankingnews.com - November 29 at 2:38 AM
Idera to Present at the 29th Annual Piper Jaffray Healthcare ConferenceIdera to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 27 at 5:25 PM
ETFs with exposure to Idera Pharmaceuticals, Inc. : November 27, 2017ETFs with exposure to Idera Pharmaceuticals, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 5:25 PM
Idera Pharmaceuticals, Inc. (IDRA) Given Consensus Rating of "Buy" by BrokeragesIdera Pharmaceuticals, Inc. (IDRA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 27 at 4:10 AM
Idera Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IDRA-US : November 21, 2017Idera Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IDRA-US : November 21, 2017
finance.yahoo.com - November 21 at 7:56 PM
$250,000.00 in Sales Expected for Idera Pharmaceuticals, Inc. (IDRA) This Quarter$250,000.00 in Sales Expected for Idera Pharmaceuticals, Inc. (IDRA) This Quarter
www.americanbankingnews.com - November 20 at 4:24 AM
Wedbush Weighs in on Idera Pharmaceuticals, Inc.s FY2017 Earnings (IDRA)Wedbush Weighs in on Idera Pharmaceuticals, Inc.'s FY2017 Earnings (IDRA)
www.americanbankingnews.com - November 20 at 3:15 AM
Zacks: Brokerages Anticipate Idera Pharmaceuticals, Inc. (IDRA) to Post -$0.08 Earnings Per ShareZacks: Brokerages Anticipate Idera Pharmaceuticals, Inc. (IDRA) to Post -$0.08 Earnings Per Share
www.americanbankingnews.com - November 18 at 7:22 PM
Biotechnology and Oncology Markets Have Positive ProjectionsBiotechnology and Oncology Markets Have Positive Projections
www.bizjournals.com - November 17 at 6:40 PM
ETFs with exposure to Idera Pharmaceuticals, Inc. : November 17, 2017ETFs with exposure to Idera Pharmaceuticals, Inc. : November 17, 2017
finance.yahoo.com - November 17 at 6:39 PM
Idera Pharmaceuticals (IDRA) and Its Competitors Head to Head ReviewIdera Pharmaceuticals (IDRA) and Its Competitors Head to Head Review
www.americanbankingnews.com - November 17 at 2:12 PM
Idera Pharmaceuticals, Inc. (IDRA) PT Set at $4.00 by HC WainwrightIdera Pharmaceuticals, Inc. (IDRA) PT Set at $4.00 by HC Wainwright
www.americanbankingnews.com - November 16 at 9:36 PM
Idera Pharmaceuticals, Inc. (IDRA) Sees Significant Decrease in Short InterestIdera Pharmaceuticals, Inc. (IDRA) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - November 12 at 1:32 AM
Short Interest Decreases By 64.5% For IDRAShort Interest Decreases By 64.5% For IDRA
www.thestreet.com - November 11 at 11:13 AM
Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC)Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC)
finance.yahoo.com - November 11 at 11:13 AM
Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 11 at 11:13 AM
Is the Options Market Predicting a Spike in Idera (IDRA) Stock?Is the Options Market Predicting a Spike in Idera (IDRA) Stock?
finance.yahoo.com - November 11 at 11:13 AM
Idera Pharmaceuticals, Inc. (IDRA) Lifted to Buy at Zacks Investment ResearchIdera Pharmaceuticals, Inc. (IDRA) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - November 10 at 12:22 AM
ETFs with exposure to Idera Pharmaceuticals, Inc. : November 7, 2017ETFs with exposure to Idera Pharmaceuticals, Inc. : November 7, 2017
finance.yahoo.com - November 8 at 10:09 AM
Todays Research Reports on Trending Tickers: Celldex Therapeutics and Idera PharmaceuticalsToday's Research Reports on Trending Tickers: Celldex Therapeutics and Idera Pharmaceuticals
finance.yahoo.com - November 8 at 10:09 AM
Idera Pharmaceuticals, Inc. (IDRA) Announces Quarterly  Earnings Results, Beats Estimates By $0.02 EPSIdera Pharmaceuticals, Inc. (IDRA) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - November 7 at 12:34 PM
Idera Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateIdera Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 2:56 AM
Idera reports 3Q lossIdera reports 3Q loss
finance.yahoo.com - November 7 at 2:56 AM
Ideras Public Offering Stinks, But Is There A Silver Lining? - Seeking AlphaIdera's Public Offering Stinks, But Is There A Silver Lining? - Seeking Alpha
seekingalpha.com - November 3 at 9:11 AM
Here's Why Idera Pharmaceuticals Jumped as Much as 11.5% TodayHere's Why Idera Pharmaceuticals Jumped as Much as 11.5% Today
finance.yahoo.com - November 3 at 9:10 AM
Idera Pharmaceuticals, Inc. (IDRA) Given Consensus Recommendation of "Hold" by BrokeragesIdera Pharmaceuticals, Inc. (IDRA) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 2 at 1:46 AM
Bros. Advisors Lp Baker Purchases 8,000,000 Shares of Idera Pharmaceuticals, Inc. (IDRA) StockBros. Advisors Lp Baker Purchases 8,000,000 Shares of Idera Pharmaceuticals, Inc. (IDRA) Stock
www.americanbankingnews.com - October 30 at 5:33 PM
Idera Pharma (IDRA) Prices 33.3M Common Stock Offering at $1.50/ShareIdera Pharma (IDRA) Prices 33.3M Common Stock Offering at $1.50/Share
www.streetinsider.com - October 27 at 6:33 AM
Short Interest In Idera Pharmaceuticals Falls 13.5%Short Interest In Idera Pharmaceuticals Falls 13.5%
www.thestreet.com - October 27 at 6:33 AM
Mid-Day Market Update: Essendant Drops After Q3 Results; Achieve Life Sciences Shares Climb - BenzingaMid-Day Market Update: Essendant Drops After Q3 Results; Achieve Life Sciences Shares Climb - Benzinga
www.benzinga.com - October 26 at 12:51 PM

SEC Filings

Idera Pharmaceuticals (NASDAQ:IDRA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Idera Pharmaceuticals (NASDAQ:IDRA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Idera Pharmaceuticals (NASDAQ IDRA) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.